- Company
- IQVIA acquires Korean healthcare marketing firm MMK
- by Eo, Yun-Ho May 18, 2021 05:52am
- The healthcare big data company IQVIA has acquired MMK Communications. Industry sources said that IQVIA Korea had completed the merger and acquisition of MMK communications, expanding its business area to digital consulting services. MMK Communications is a company that provides digital detailing services including webinars and call ce
- Company
- 11 companies join the use patent for Entresto
- by Kim, Jin-Gu May 18, 2021 05:51am
- While Hanmi filed an invalidation trial with Entresto's use patent and composition patent, 11 companies, including Daewoong and Chong Kun Dang, filed for the same judgment. According to the pharmaceutical industry on the 13th, 10 companies including Chong Kun Dang, Yooyoung, Hanlim, Hana, Ahn-gook, Boryung, Yuyu, Genuonesciences, Kolmar, a
- Company
- Negotiations on the drug price of Onivyde have begun
- by Eo, Yun-Ho May 14, 2021 05:50am
- The new pancreatic cancer drug "Onivyde" is in the final stages of listing insurance benefits. According to related industries, Servier Korea has recently entered pharmaceutical negotiations with the NHIS for the registration of Onivyde (Irinotecan HCl) under the order of the MOHW. As a result, attention is being paid to whether a new insu
- Company
- Will Lipitor Plus be able to continue Lipitor’s legacy?
- by Eo, Yun-Ho May 13, 2021 05:57am
- Whether Viatris Korea, which owns the original atorvastatin ‘Lipitor,’ will be able to perform as well in the ‘ezetimibe’ combination therapy market, is drawing attention. Recently, the use of combination therapy in dyslipidemia patients has become more than a strategic treatment option - it has become a main trend in the market.
- Company
- Which company signed the CMO deal? Rumors rampant
- by Kim, Jin-Gu May 13, 2021 05:57am
- Rumors on CMO production of COVID-19 vaccines by domestic companies continue. Rumors are rife on which company would be producing which vaccine. Repeatedly, a specific company is mentioned by some, then the rumor is denied by that company. On the 12th, Samsung Biologics publically announced that the reports that it will produce Pfizer’s
- Company
- It's not far from conquering lung cancer
- by An, Kyung-Jin May 13, 2021 05:56am
- Choi, a woman in her 50s who lives in Seongbuk-gu, Seoul, was diagnosed with stage 4 lung cancer last year and was disappointed. At the time of diagnosis, metastases had occurred in various organs, including the brain, eyeballs, and bones, so it was impossible to participate in clinical research as well as surgery. Fortunately, EGFR targeted
- Company
- Celltrion Exports COVID-19 treatments to Pakistan
- by Chon, Seung-Hyun May 13, 2021 05:55am
- Regkirona, COVID-19 antibody treatment developed by Celltrion, will be sold overseas. Celltrion Healthcare announced on the 10th that it plans to sign a contract for 100,000 vials of Regkirona with a subsidiary of Pakistan's largest order factories (POF) under the Ministry of National Defense and ship the contract. "Regkirona has been a
- Company
- Chong Kun Dang challenges New Biologics
- by An, Kyung-Jin May 13, 2021 05:55am
- Chong Kun Dang is a new drug developer and challenges to overcome lung cancer tolerance with a dual anti-cancer antibody that simultaneously inhibits hepatocellular growth factor receptor (cMET) and epithelial cell growth factor receptor (EGFR). It is planning to achieve both business performance and R&D performance with bio-new drugs that it is
- Company
- HER2-directed ADC ‘Enhertu’ in process of seeking approval
- by Eo, Yun-Ho May 12, 2021 04:43pm
- A HER2-directed antibody-drug conjugate (ADC) is looking to enter the Korean market. According to industry officials, AstraZeneca Korea and Daiichi Sankyo Korea are preparing the application process for the approval of their human epidermal growth factor receptor 2 (HER2)-directed antibody-drug conjugate (ADC) ‘Enhertu (trastuzumab derux
